8-K 1 biosigtechnologies8k101614.htm 8-K biosigtechnologies8k101614.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C.  20549
 
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
 
Date of Report (Date of earliest event reported):  October 6, 2014
 
BioSig Technologies, Inc.
(Exact name of registrant as specified in its charter)
 
Delaware
333-190080
26-4333375
(State or other jurisdiction
of incorporation)
(Commission File Number)
(IRS Employer
Identification No.)

12424 Wilshire Boulevard, Suite 745
Los Angeles, California
90025
(Address of principal executive offices)
(Zip Code)

Registrant’s telephone number, including area code: (310) 820-8100

                                                                                                                         
(Former name or former address, if changed since last report)
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 
 

Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On October 6, 2014, Kalyanam Skivkumar, M.D. Ph.D. submitted his resignation as a member of the board of directors (the “Board”) of BioSig Technologies, Inc. (the “Company”), subject to acceptance by the Board, which occurred on October 14, 2014. Dr. Skivkumar is not resigning because of a disagreement with the Company or on any other matter relating to its operations, policies or practices.
 
 
 
 

 
 
 
 
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
BIOSIG TECHNOLOGIES, INC.
  
     
     
Date: October 16, 2014 
By:
/s/ Gregory Cash  
    Name: Gregory Cash  
    Title: Chief Executive Officer